Skip to main content
SpringerLink
Log in

Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Four proton pump inhibitors (PPIs) are currently marketed in various parts of the world, and all of these (lansoprazole, omeprazole, pantoprazole, and rabeprazole) are available for prescription use in the United States. As a therapeutic group, the PPIs are highly useful for the relief of symptoms and healing of gastroesophageal reflux disease, gastric and duodenal ulcer disease, eradication of Helicobacter pylori infection, prevention and treatment of nonsteroidal antiinflammatory drug (NSAID)-associated damage, management of hypersecretory states such as Zollinger-Ellison syndrome, and care of patients with non-variceal upper gastrointestinal bleeding, or non-ulcer dyspepsia. The pathophysiologic basis of these management benefits lies in the potent gastric acid inhibitory effects of the PPIs. There are differences between the PPIs in their pharmacokinetics, pharmacodynamics, influence by food and antacids, clinical efficacy, and potential for drug interactions. It is not always clear whether these often subtle variations are necessarily of clinical importance. The physician's choice of one PPI over another must rest with her/his interpretation of the clinical importance of the generally small differences between PPIs, their approval for treatment of specific clinical indications within the physician's practice jurisdiction, and the strength of the evidence based on the quantity and quality of the supporting clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Stedman CAM, Barclay ML: Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000, 14:963–978.

    Article  PubMed  CAS  Google Scholar 

  2. Richardson P, Hawkey CJ, Stack WA: Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998, 56:307–335.

    Article  PubMed  CAS  Google Scholar 

  3. Humphries TJ, Merritt GJ: Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999, 13(suppl 3):S18. The pharmacokinetics of some drugs, such as warfarin and digoxin, have a relatively narrow therapeutic range. This review paper considers the potential for clinically significant drug interactions with proton pump inhibitors. The newer PPIs, pantoprazole and rabeprazole, appear less likely to induce or to inhibit the cytochrome P-450 enzyme system.

    Article  Google Scholar 

  4. Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990, 99:345–351.

    PubMed  CAS  Google Scholar 

  5. Bell NJ, Hunt RH: Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992, 33:118–124.

    PubMed  CAS  Google Scholar 

  6. Kromer W, Horbach S, Luhmann R: Relative efficacies of gastric proton pump inihibitors: their clinical and pharmacological basis. Pharmacology 1999, 59:57–77.

    Article  PubMed  CAS  Google Scholar 

  7. Tolman KG, Sanders, SW, Buchi KN: Gastric pH levels after 15 mg and 30 mg lansoprazole or 20 mg omeprazole [abstract]. Gastroenterology 1994, 106:A172.

    Google Scholar 

  8. Seensalu R, Iwarzon M, Haczewska I: Dose-response comparison of lansoprazole and omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers [abstract]. Gastroenterology 1995, 108:A215.

    Article  Google Scholar 

  9. Verdu EF, Fraser R, Armstrong D, Blum AL: Lansoprazole and omeprazole at therapeutic doses, produce equivalent rises in gastric pH in Helicobacter pylori (Hp) positive subjects [abstract]. Gastroenterology 1994, 106:A205.

    Google Scholar 

  10. Geus WP, Mulder PG, Nicolai JJ, et al.: Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Phamracol Ther 1998, 12:329–335.

    Article  CAS  Google Scholar 

  11. Dammann HG, Fuchs W, Richter G, et al.: Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997, 11:359–364.

    Article  PubMed  CAS  Google Scholar 

  12. Huang J, Goldwater D, Thomson A, et al.: Lansoprazole achieves faster control of intragastric acidity than pantoprazole [abstract]. Gut 1999, 45:A102.

    Article  Google Scholar 

  13. Meyer UA: Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur J Gastroenterol Hepatol 1996, 8(suppl 1):S21-S25.

    PubMed  Google Scholar 

  14. Pantofickova D, Dorta G, Jornod P, et al.: Identification of the characteristics influencing the degree of antisecretory activity of PPIs [abstract]. Gastroenterology 2000, 118:A1290.

    Google Scholar 

  15. Festen HMP: Profound gastric acid inhibition, advantages and potential hazards. Scand J Gastroenterol 1989, 171:99–105.

    Google Scholar 

  16. Porro GB, Lazzaroni M, Cardelli A: Pantoprazole vs omeprazole in the treatment of duodenal ulcer. Argomenti di Gastroenterol Clin 1994, 7:271–275.

    Google Scholar 

  17. Dekkers CPM, Beker JA, Thjodleifsson B, et al.: Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999, 13:179–186.

    Article  PubMed  CAS  Google Scholar 

  18. Rehner M, Rohner HG, Schepp W: Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration: a multicentre study. Aliment Pharmacol Ther 1995, 9:411–416.

    Article  PubMed  CAS  Google Scholar 

  19. Vicari F, Belin J, Marek L: Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: results of a French multicentric double-blind comparative trial [abstract]. Gastroenterology 1998, 114:G1324.

    Google Scholar 

  20. Thjodleifsson B, Beker J, Dekkers C, et al.: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease. Dig Dis Sci 2000, 45:845–853. Both 10-mg and 20-mg doses of rabeprazole, given each morning, are equivalent to omeprazole, 20 mg, in preventing recurrence of erosive gastroesophageal reflux disease.

    Article  PubMed  CAS  Google Scholar 

  21. Mössner J, Koop H, Porst H: One-year prophylactic efficacy and safety of pantoprazole in healed reflux oesophagitis [abstract]. Gut 1996, 39:A602.

    Google Scholar 

  22. Van Rensburg CJ, Honiball PJ, Gundling HDK: Prophylactic efficacy and safety of 40 mg pantoprazole against relapse in patients with healed reflux oesophagitis: a two-year study [abstract]. Gut 1996, 39:A603.

    Google Scholar 

  23. Bardhan KD, Ahlberg J, Hislop WS, et al.: Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 1994, 8:215–220.

    Article  PubMed  CAS  Google Scholar 

  24. Lauritsen K, Jaup B, Carling L, et al.: Efficacy of pantoprazole compared with omeprazole in prevention of relapse of reflux esophagitis: double blind randomized multicenter trial [abstract]. Gastroenterology 2000, 118:A1290.

    Article  Google Scholar 

  25. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338:727–734.

    Article  PubMed  CAS  Google Scholar 

  26. Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338:719–726.

    Article  PubMed  CAS  Google Scholar 

  27. Talley NJ, Meineche-Schmidt V, Pare P, et al.: Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the BOND and OPERA studies). Aliment Pharmacol Ther 1998, 12:1055–1065.

    Article  PubMed  CAS  Google Scholar 

  28. Penston JG, McColl KEL: Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997, 43:223–243.

    Article  PubMed  CAS  Google Scholar 

  29. Lundell L, Havu N, Andersson A: Gastritis development and acid suppression therapy revisited: results of a randomized clinical study with long-term follow up [abstract]. Gastroenterology 1997, 112:A28.

    Google Scholar 

  30. Fitton A, Wiseman L: Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996, 51:460–482.

    Article  PubMed  CAS  Google Scholar 

  31. Lind T, Rydberg L, Kyleback A, et al.: Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-esophageal reflux disease. Aliment Pharmacol Ther 2000, 14:861–867. Esomeprazole, 20 mg/d, was superior to omeprazole, 20 mg/d, in the maintenance of intragastric pH over 4, and in median 24-hour intragastric pH values, whereas the area under the plasma concentration- time curve (AUC) was 80% higher for esomeprazole, 20 mg, versus omeprazole.

    Article  PubMed  CAS  Google Scholar 

  32. Ekstrom P, Carling L, Unge P, et al.: Lansoprazole versus omeprazole in active duodenal ulcer: a double-blind, randomized, comparative study. Scand J Gastroenterol 1995, 30:210–215.

    PubMed  CAS  Google Scholar 

  33. Chang F-Y, Chiang C-Y, Tam T-N, et al.: Comparison of lansoprazole and omeprazole in the short-term management of duodenal ulcers in Taiwan. J Gastroenterol Hepatol 1995, 10:595–601.

    PubMed  CAS  Google Scholar 

  34. Dobrilla G, Piazzi L, Fiocca R: Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. Clin Ther 1999, 21:1321–1332.

    Article  PubMed  CAS  Google Scholar 

  35. Petite J-P, Slama J-L, Licht H, et al.: Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. Gastroenterol Clin Biol 1993, 17:334–0340.

    PubMed  CAS  Google Scholar 

  36. Beker JA, Bianchi Porro G, Bigard MA, et al.: Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995, 7:407–410.

    PubMed  CAS  Google Scholar 

  37. Witzel L, Gutz H, Huttemann W, et al.: Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995, 9:19–24.

    Article  PubMed  CAS  Google Scholar 

  38. Dekkers CPM, Beker JA, Thjodleifsson B, et al.: Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer: a European multicenter study. Aliment Pharmaol Ther 1998, 12:789–795.

    Article  CAS  Google Scholar 

  39. Petite JP, Salducci J, Grimaud JC, et al.: Lansoprazole versus omeprazole in the treatment of reflux oesophagitis. Med Chir Dig 1995, 24:291–294.

    Google Scholar 

  40. Castell DO, Richter JE, Robinson M, et al.: Efficacy and safety of lansoprazole in the treatment of erosive esophagitis. Am J Gastroenterol 1996, 91:1749–1757.

    PubMed  CAS  Google Scholar 

  41. Mee AS, Rowley JL: Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996, 10:757–763.

    Article  PubMed  CAS  Google Scholar 

  42. Mulder CJ, Dekker W, Gerretsen: Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVA (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996, 8:1101–1106.

    Article  PubMed  CAS  Google Scholar 

  43. Corallo J, Vicari F, Forestier S, et al.: Lansoprazole in acute treatment of reflux esophagitis [abstract]. Gastroenterology 1993, 104:A58.

    Google Scholar 

  44. Hatlebakk JG, Berstad JA, Carling L, et al.: Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993, 28:224–228.

    PubMed  CAS  Google Scholar 

  45. Carling L, Axelsson CK, Forssell H, et al.: Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study. Aliment Pharmacol Ther 1998, 12:985–990.

    Article  PubMed  CAS  Google Scholar 

  46. Jasperson D, Diehl KL, Schoeppner H, et al.: A comparison of omeprazole, lansoprazole and pantoprazole in maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998, 12:49–52.

    Article  Google Scholar 

  47. Mössner J, Holscher AH, Herz R, et al.: A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther 1995, 9:321–326.

    Article  PubMed  Google Scholar 

  48. Corinaldesi R, Valetini M, Belaiche J, et al.: Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study. Aliment Pharmacol Ther 1995, 9:667–671.

    Article  PubMed  CAS  Google Scholar 

  49. Hotz J, Gangl A, Heinzerling H: Pantoprazole vs. omeprazole in acute reflux esophagitis [abstract]. Gastroenterology 1996, 110:A136.

    Google Scholar 

  50. Thjodleifsson B, Dekkers CPM, Beker JA, et al.: Rabeprazole 20 mg/day is similar to omeprazole 20 mg/day in the treatment of erosive or ulcerative oesophagitis [abstract]. Gastroenterology 1997, 112:A312.

    Google Scholar 

  51. Dekkers CPM, Beker JA, Thjodleifsson B, et al.: Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999, 13:49–57.

    Article  PubMed  CAS  Google Scholar 

  52. Gisbert JP Bioxida D, Aller R, et al.: Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence. Med Clin (Barc) 1999, 112:161–165.

    CAS  Google Scholar 

  53. Miwa H, Nagahara A, Sato K, et al.: Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. J Gastroenterol Hepatol 1999, 14:317–321. The new PPI rabeprazole offers effective eradication of H. pylori infection when combined with amoxicillin and clarithromycin with rates comparable to those achieved with lansoprazole in a 1-week twice-daily regimen.

    Article  PubMed  CAS  Google Scholar 

  54. Miwa H, Nagahara A, Sato K, et al.: Efficacy of 1 week PPI/AC therapy for H. pylori infection in the Japanese population. J Gastroenterol Hepatol 1999, 14:305–309.

    Article  Google Scholar 

  55. Mullhaupt B, Fluckiger T, Frohli P, et al.: One week low dose triple therapies with lansoprazole or omeprazole are equally effective for H pylori eradication and ulcer healing [abstract]. Gastroenterology 1996, 110:A202.

    Google Scholar 

  56. Misiewicz JJ, Harris AW, Bardhan KD, et al.: One week triple therapy for Helicobacter pylori: a multicentre comparative study: Lansoprazole Helicobacter Study Group. Gut 1997, 41:735–739.

    Article  PubMed  CAS  Google Scholar 

  57. Spinzi GC, Bierti L, Bortoli A, et al.: Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998, 12:433–438.

    Article  PubMed  CAS  Google Scholar 

  58. Sito E, Konturek PC, Bielanski W, et al.: One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter infection in duodenal ulcer patients. J Physiol Pharmacol 1996, 47:221–228.

    PubMed  CAS  Google Scholar 

  59. Janssen Pharmaceutica. Available at http://www.us.janssen.com/products

  60. Prevacid. Available at http://www.prevacid.com (registration required)

  61. Astrazenica Pharmaceuticals. Available at http://www.astrazeneca-us.com

  62. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Available at http://www.fda.gov/cder

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, University of Alberta, 519 Newton Research Building, T6G 2C2, Edmonton, AB, Canada

    Alan B. R. Thomson MD

Authors
  1. Alan B. R. Thomson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomson, A.B.R. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2, 482–493 (2000). https://doi.org/10.1007/s11894-000-0013-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-000-0013-0

Keywords

Search

Navigation